Literature DB >> 2161782

Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma.

G Atlante1, M Pozzi, C Vincenzoni, G Vocaturo.   

Abstract

In recent years, the association between breast and endometrial cancer has been the subject of many studies. The present report describes four cases of this association in which tamoxifen had been administered to all of the patients. Data have been published regarding the possibility that tamoxifen may be responsible for the subsequent development of carcinoma of the corpus uteri in these patients. The authors intend to carry out a case-control study on patients treated with tamoxifen for breast carcinoma to reveal the possible presence of endometrial carcinoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161782     DOI: 10.1016/0090-8258(90)90371-q

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Suppression of Estrogenic Activity by Medroxyprogesterone Acetate in Tamoxifen-treated Patients after Surgery for Breast Cancer to Reduce the Risk of Endometrial Cancer Development.

Authors: 
Journal:  Breast Cancer       Date:  1996-03-29       Impact factor: 4.239

2.  Tamoxifen and cancer of the endometrium.

Authors:  G O'Connell; A Arnold
Journal:  CMAJ       Date:  1993-06-15       Impact factor: 8.262

Review 3.  Gynecologic effects of tamoxifen: case reports and review of the literature.

Authors:  R M Caputo; L J Copeland
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1996

Review 4.  Gynaecologic effects of tamoxifen.

Authors:  D Y Kuo; C D Runowicz
Journal:  Med Oncol       Date:  1995-06       Impact factor: 3.064

Review 5.  What do we know and what don't we know about tamoxifen in the human uterus.

Authors:  A Friedl; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 6.  Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer.

Authors:  V C Jordan
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

Review 7.  A risk-benefit assessment of tamoxifen therapy.

Authors:  W H Catherino; V C Jordan
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606

8.  The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ.

Authors:  D Robinson; L Holmberg; H Møller
Journal:  Br J Cancer       Date:  2008-07-29       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.